CD274 and renal cell carcinoma: Further evidence of the lack of effectiveness of anti–PD-L1 agents in RCC comes from the IMmotion010 trial,5 in which adjuvant atezolizumab did not affect disease-free survival in intermediate-to-high-risk resected or stage M1 cancer in patients with no evidence of disease.